WO1992018133A1 - Method of treatment using steroid mouthwash - Google Patents
Method of treatment using steroid mouthwash Download PDFInfo
- Publication number
- WO1992018133A1 WO1992018133A1 PCT/US1992/002806 US9202806W WO9218133A1 WO 1992018133 A1 WO1992018133 A1 WO 1992018133A1 US 9202806 W US9202806 W US 9202806W WO 9218133 A1 WO9218133 A1 WO 9218133A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- composition
- steroid
- inflammatory
- derivative
- antifungal agent
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/63—Steroids; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/494—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with more than one nitrogen as the only hetero atom
- A61K8/4946—Imidazoles or their condensed derivatives, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/60—Sugars; Derivatives thereof
- A61K8/602—Glycosides, e.g. rutin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q11/00—Preparations for care of the teeth, of the oral cavity or of dentures; Dentifrices, e.g. toothpastes; Mouth rinses
Definitions
- the invention is related to treatment of inflammatory diseases of the mouth using anti-inflammatory steroids in combination with antifungal drugs in an aqueous medium as a mouthwash.
- Treatment with topical corticosteroids as presently formulated and administered has significant limitations.
- Existing commercially available compositions are usually supplied as creams, gels, or ointments that are intended for cutaneous applications. Such preparations are not readily acceptable to patients for use on the mucosa.
- the prior art compositions must be applied frequently (up to six times a day) .
- the compositions are not readily applied to the areas of the oral cavity that are difficult to reach.
- treatment with ste ⁇ roids causes increased susceptibility to fungal infections of the mouth. This complication is especially common in patients suffering from oral lichen planus, a condition in which Candida is found to colonize mouth lesions in 25% of the patients.
- Kena- log (TM) 10 Injection is an aqueous suspension used for intradermal, intra-articular, and intrabursal administra ⁇ tion.
- the suspension is not appropriate for use intrave ⁇ nously or intramuscularly, and there is no suggestion that the suspension can be used as a mouthwash or swish for treatment of inflammatory diseases of the oral cavity.
- Aristospan (TM) is also used as a suspension for intrale- sional administration and is available as a cream for topical application.
- Kenalog-H (TM) cream is applied topically to the skin. All of these preparations have, as an untoward effect, an increased susceptibility to fungal infections.
- a preparation containing an antifungal, nystatin, and a steroid, triamcinolone acetonide, is pro ⁇ vided as a cream under the trade name Mycolog II. It is not appropriate for use as a mouthwash.
- a preparation containing nystatin for use as a swish (mouthwash) has been available. However, that preparation does not contain any anti-inflammatory steroid as an active agent.
- R. A. Cawson (Treatment of Oral Lichen Planus with Betamethasone", British Medical Journal. (January 13, 1968)) teaches the use of betamethasone pellets to treat oral lichen planus. Use of hydrocortisone pellets was also tried. The betamethasone pellets were efficacious. Hydro ⁇ cortisone pellets were also tried but were rarely effec ⁇ tive, even when combined with tetracycline mouthwashes.
- Rothwell and Spektor discloses method of treating patients undergoing irradiation therapy comprising prophylactic use of mouth rinse with a solution containing tetracycline, 500 mg; nystatin, 1,200,000 U; hydrocortisone, 100 mg; and diphen- hydramine elixir, 10 ml. to make a solution of 25 ml. It is taught that tetracycline is unstable in solution and was, therefore, dispensed as a separate solution. It is not clear if the tetracycline was mixed with the other active agents just before using the rinse. However, the method taught therein was not used to treat existing, chronic inflammatory problems such as oral lichen planus.
- the object of the present invention is to provide a means of treating patients suffering from inflammatory conditions of the mouth using aqueous anti-inflammatory steroids in solutions that can be swished and expectorated as a mouthwash.
- Such therapy would allow direct contact of the medication with the diseased mucous membranes and would contact areas of the oral cavity that would not usually be reached with application of creams, gels, or ointments.
- the com ⁇ bination of active agents would alleviate the inflammatory condition while inhibiting the growth of Candida species.
- the use of such mouthwashes would result in efficient ap ⁇ plication of both agents to all of the surfaces of the oral cavity, including areas that would not be readily reached by application of gels, creams, or ointments. Swishing for three to five minutes, then expectorating the aqueous anti-inflammatory-containing, results in main ⁇ tenance of contact of the active agents with the oral cavity surfaces for a longer time than would application of gels containing those agents.
- the mode of application is simple and is not repugnant to the patient as is the ap ⁇ plication of creams, gels, or ointments.
- compositions used as mouthwashes preferably should be in the acidic range since most of the steroids and anti ⁇ fungal agents are more soluble in acidic solutions.
- a pH of 3.5 to 7 is desirable, with a pH of 4 to 6.5 being more preferable.
- a solution having a pH of less than 4 would be likely to cause a stinging sensation.
- Steroids and anti- fungal agents are usually less soluble at pH higher than 7. Furthermore, at higher pH the solutions are often unpleas ⁇ ant to use.
- Anti-inflammatory steroids are classified according to anti-inflammatory efficacy of the preparation or according to relative effectiveness of the particular active agent used, (i.e., How much active agent is required to obtain a given effect?) Cornell and Soughton, assigning efficacy to each preparation, assign a low efficacy to some prepara- tions of hydrocortisone.
- a second method of classification ranking relative anti-inflammatory potency ranks anti- inflammatory agents in relation to the amount of agent needed to obtain a given anti-inflammatory effect wherein the more effective agents having a higher number assigned with a ranking of one given to hydrocortisone. Hydrocor ⁇ tisone at a ranking of 1 and is listed as requiring an approximate dosage of 20 mg.
- Steroids particularly suggest ⁇ ed for use in the method of the invention are triamcinolone and derivatives (particularly diacetate, hexacetonide, and acetonide) , betamethasone and its derivatives (including particularly the dipropionate, benzoate, sodium phosphate, acetate, and valerate) , flunisolide, prednisone and its derivatives, fluocinolone and its derivatives (particularly the acetonide) , diflorasone and derivatives (particularly the diacetate) , halcinonide, desoximetasone, clobetasol (especially the propionate) , alclometasone, fluticasone (particularly the propionate) and desonide.
- the effective concentration of drug will vary with the active agent used. Concentration would fall within the 0.01% to 1% range. For example, for betamethasone and its derivatives the pre ⁇ ferred concentration would be 0.01% to 0.2% while the preferred concentration of triamcinolones would be 0.025% to 1%.
- the preferred antifungal agents used in the method of the invention show great effectiveness against Candida species and are poorly absorbed from the mucosa of the intestinal tract. Some preferred antifungal agents are nystatin, clotrimazole, econazole, oxiconazole, keto ⁇ on- azole, miconazole, ciclopirax olamine, amphotericin B, and sulconazole, all of which are poorly absorbed from the intestinal tract. Nystatin and clotrimazole are partic ⁇ ularly preferred agents.
- the aqueous solution may contain buffers, surfac ⁇ tants, humectants, preservatives, flavorings, stabilizers (including antioxidants) colorants, and other additives used in solutions administered into the oral cavity.
- buffers surfac ⁇ tants
- humectants preservatives
- flavorings include antioxidants
- stabilizers including antioxidants
- colorants include colorants
- other additives used in solutions administered into the oral cavity.
- other medicinal agents may be added for purposes of alleviating other undesirable conditions in the mouth.
- Such agents could include, for example, analgesics, anti ⁇ bacterial agents, and emollients.
- any buffer system commonly used for preparing medicinal compositions would be appropriate.
- Flavorings used in the dentifrice art such as pepper ⁇ mint, citrus flavorings, berry flavorings, vanilla, cin ⁇ namon, and sweeteners, either natural or artificial, could be used in compositions of the invention.
- the vehicle used generally is primarily water, other vehicles may be present such as alcohols, glycols (polyethylene glycol or polypropylene glycol are examples) , glycerin, and the like may be used to solubilize the active agents.
- Surfactants may include anionic, nonionic, ampho- teric and cationic surfactants which are known in the art as appropriate ingredients for mouthwashes.
- Suitable preservatives include, but are not limited to, butylated hydroxyanisole (BHA) , butylated hydroxy- toluene (BHT) , benzoic acid, and ascorbic acid.
- a buffered solution containing benzalkonium chloride 0.02%, and 0.1% benzoic acid in water is adjusted to pH 4.5 with sodium benzoate.
- Betamethasone dipropionate and nystatin are added in sufficient quantities to provide a composition having a concentration of active agents in excess of 0.05% of betamethasone dipropionate and 100,000 units nystatin per ml.
- the pH is again adjusted to 4.5 and sufficient buffered solution added to provide a composition having 0.05% betamethasone dipropionate and nystatin 100,000 units per ml. (A dose for swishing is 5 ml.)
- the solution is supplied in sealed containers contain ⁇ ing 5 ml.
- the patient is instructed to use one container full three times daily at least three hours before the next meal.
- the teeth should be cleaned and the mouth rinsed.
- the solution is to be swished around in the mouth for at least 3 minutes, then expectorated. None is to be taken by mouth for at least 30 minutes after use of the mouth wash.
- EXAMPLE 2 EXAMPLE 2 :
- a composition is prepared in the manner disclosed in Example 1.
- the active anti-inflammatory agent used is triamcinolone added in an amount to provide a final product having triamcinolone 0.1% and nystatin 100,000 units per ml.
- the composition is packaged in individual doses of 5 ml. in sealed containers. Instructions for use are the same as those for the composition of Example 1.
- a mouthwash is prepared as indicated in Example 1. However, the preparation is packaged in a bottle containing multiple doses. The patient is instructed to use one tea ⁇ spoon of fluid three times daily at least three hours before the next meal. Before use, the teeth should be cleaned and the mouth rinsed. The solution is to be swished around in the mouth for at least 3 minutes, then expectorated. None is to be taken by mouth for at least 30 minutes after use of the mouthwash.
- a mouthwash composition is prepared by the method used in Example 1 except that the active agents are replaced with clobetasol propionate 0.05% as the anti-inflammatory steroid and, as the antifungal agent, oxiconazole nitrate 1%.
- a mouthwash composition is prepared by the method of Example 1 except that the active agents are replaced with the steroid alclometasone dipropionate 0.05% and, as the antifungal agent, oxiconazole nitrate 1%.
- Example 6 A mouthwash composition is prepared by the method of Example 1 except that the active agents are replaced with the steroid fluticasone propionate 0.05%.
- Example 7 A mouthwash composition is prepared by the method of Example 1 except that the active agents are replaced with the steroid fluticasone propionate 0.05%.
- a mouthwash composition is prepared by the method of Example 2 except that the concentration of triamcinolone is .5%. Nystatin dosage is still 100,000 U/ml.
- a mouthwash composition is prepared in accord with the method of Example 1 except that the antifungal agent was clotrimazole 1%.
- Mouthwash of Example 2 Mouthwash of Example 7: Mouthwash of Example 8: ++++/ ++++
- the use of the swish in accord with the teachings of the specification provides greatly increased therapeutic relief in the treatment of the cited inflammatory conditions of the mouth.
- the use of the liquid mouthwash preparation as described provides substantial benefit over the commercial products of the art.
- other anti-inflammatory steroids could be chosen from among those having a potency of ⁇ 2.5 in relation to hydro ⁇ cortisone and other antifungal agents, especially those that are poorly absorbed in the gastrointestinal tract, could be used in accord with the teachings of this disclo- sure without departing from the spirit of the invention.
- the compositions of the invention containing anti- inflammatory agents and antifungal agents can be used for veterinary purposes as well. However, when so used the therapeutic compositon would be sprayed into the oral cavity after the teeth of the animal have been cleaned.
- the animal would then be prevented from ingestion of food or water for about 30 minutes
Abstract
Description
Claims
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US802,646 | 1985-11-27 | ||
US68338091A | 1991-04-11 | 1991-04-11 | |
US683,380 | 1991-04-11 | ||
US80264691A | 1991-12-09 | 1991-12-09 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1992018133A1 true WO1992018133A1 (en) | 1992-10-29 |
Family
ID=27103091
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1992/002806 WO1992018133A1 (en) | 1991-04-11 | 1992-04-10 | Method of treatment using steroid mouthwash |
Country Status (4)
Country | Link |
---|---|
EP (1) | EP0579760A4 (en) |
AU (1) | AU1779192A (en) |
CA (1) | CA2103351C (en) |
WO (1) | WO1992018133A1 (en) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1994016710A1 (en) * | 1993-01-21 | 1994-08-04 | Janssen Pharmaceutica N.V. | Topical ketoconazole compositions |
US5993787A (en) * | 1996-09-13 | 1999-11-30 | Johnson & Johnson Consumer Products, Inc. | Composition base for topical therapeutic and cosmetic preparations |
EP1567113A2 (en) * | 2002-10-24 | 2005-08-31 | Jay A. Goldstein | Antifungal formulations |
WO2009043134A1 (en) | 2007-10-03 | 2009-04-09 | Myrex Pharmaceuticals Inc. | Mouthwash and method of using same for the treatment of mucositis or stomatitis |
WO2017129457A1 (en) * | 2016-01-27 | 2017-08-03 | Peter Sommer | Pharmaceutical preparation and the use thereof for viral inflammatory disorders of the upper respiratory tract |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NZ530915A (en) * | 2004-02-02 | 2004-08-27 | Bernard Charles Sherman | Antimicrobial oral rinse solid composition to be dispersed in water prior to use in the oral cavity |
-
1992
- 1992-04-10 CA CA 2103351 patent/CA2103351C/en not_active Expired - Fee Related
- 1992-04-10 AU AU17791/92A patent/AU1779192A/en not_active Abandoned
- 1992-04-10 WO PCT/US1992/002806 patent/WO1992018133A1/en not_active Application Discontinuation
- 1992-04-10 EP EP92911000A patent/EP0579760A4/en not_active Ceased
Non-Patent Citations (7)
Title |
---|
Chemical Engineer's Handbook, 1973, PERRY, pages 22-52, see entire page. * |
Facts and Comparisons, 1992, see entire document. * |
Merck Index, 1976, pages 309,310,875,876, see entire 623,2370,6547. * |
Remingtons 17, 1985, see entire document. * |
See also references of EP0579760A4 * |
Special Care in Dentistry, January-February 1990, ROTHWELL, Palliation of radiation-related mucositis", pages 21-25, see entire document. * |
US Pharmacopeia, The National Formulary, 1980, see entire document. * |
Cited By (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1994016710A1 (en) * | 1993-01-21 | 1994-08-04 | Janssen Pharmaceutica N.V. | Topical ketoconazole compositions |
US5654293A (en) * | 1993-01-21 | 1997-08-05 | Janssen Pharmaceutica N.V. | Topical oil-in-water emulsion compositions containing ketoconazole and an acetonide glucocorticosteroid |
AU683865B2 (en) * | 1993-01-21 | 1997-11-27 | Janssen Pharmaceutica N.V. | Topical ketoconazole compositions |
CN1096860C (en) * | 1993-01-21 | 2002-12-25 | 詹森药业有限公司 | Topical ketoconazole compositions |
US5993787A (en) * | 1996-09-13 | 1999-11-30 | Johnson & Johnson Consumer Products, Inc. | Composition base for topical therapeutic and cosmetic preparations |
EP1567113A2 (en) * | 2002-10-24 | 2005-08-31 | Jay A. Goldstein | Antifungal formulations |
EP1567113A4 (en) * | 2002-10-24 | 2006-11-08 | G & R Pharmaceuticals Llc | Antifungal formulations |
US8232304B2 (en) | 2002-10-24 | 2012-07-31 | G & R Pharmaceuticals, Llc | Antifungal formulations |
WO2009043134A1 (en) | 2007-10-03 | 2009-04-09 | Myrex Pharmaceuticals Inc. | Mouthwash and method of using same for the treatment of mucositis or stomatitis |
EP2203152A1 (en) * | 2007-10-03 | 2010-07-07 | Myrex Pharmaceuticals INC. | Mouthwash and method of using same for the treatment of mucositis or stomatitis |
EP2203152A4 (en) * | 2007-10-03 | 2011-05-25 | Myrex Pharmaceuticals Inc | Mouthwash and method of using same for the treatment of mucositis or stomatitis |
WO2017129457A1 (en) * | 2016-01-27 | 2017-08-03 | Peter Sommer | Pharmaceutical preparation and the use thereof for viral inflammatory disorders of the upper respiratory tract |
Also Published As
Publication number | Publication date |
---|---|
CA2103351A1 (en) | 1992-10-29 |
EP0579760A4 (en) | 1995-07-05 |
CA2103351C (en) | 2000-01-25 |
AU1779192A (en) | 1992-11-17 |
EP0579760A1 (en) | 1994-01-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US5310545A (en) | Method of treatment using mouthwashes containing steroids and antifungal agents and compositions of matter | |
US5407663A (en) | Method of treating inflammatory conditions of the mouth using steroid containing mouthwash which may contain antifungal agents | |
Goodfellow et al. | Oral spironolactone improves acne vulgaris and reduces sebum excretion | |
McCreary et al. | Clinical management of oral lichen planus | |
EP0928184B1 (en) | Anti-caries oral compositions | |
US3856934A (en) | Skin depigmentation | |
JP5684454B2 (en) | Oral care therapeutic and prophylactic compositions | |
US6610276B2 (en) | Multi-functional dental composition | |
Ortonne et al. | Comparative study of ketoconazole 2% foaming gel and betamethasone dipropionate 0.05% lotion in the treatment of seborrhoeic dermatitis in adults | |
US20040138179A1 (en) | Antifungal formulations | |
JPH02501739A (en) | steroid lotion | |
NZ240390A (en) | Anti-plaque/gingivitis composition comprising a morpholinoamino alcohol and a chelating agent | |
HU221319B1 (en) | Topical ketoconazole compositions and process for their preparation | |
JP2014208709A (en) | Use of chitosan for treatment of nail inflammatory diseases | |
Lassus et al. | A dimethoxynaphthalene derivative (RS‐43179 gel) compared with 0.025% fluocinolone acetonide gel in the treatment of psoriasis | |
WO1992007548A1 (en) | Improved anti-plaque compositions comprising a combination of morpholinoamino alcohol and chelating agent | |
JP5730025B2 (en) | Oral composition | |
Holbrook et al. | Aqueous hydrocortisone mouthwash solution: clinical evaluation | |
CA2103351C (en) | Method of treatment using steroid mouthwash | |
JP3685470B2 (en) | Composition for promoting oral hygiene | |
WO1998051316A1 (en) | Pharmaceutical formulations containing colostrum and the use of colostrum for the treatment of affections of the oral cavity | |
KR100333445B1 (en) | Composition for enhancing oral hygiene | |
JP3060238B2 (en) | Oral composition | |
JPH05194219A (en) | Fungicidal agent for topical application | |
WO2010109423A1 (en) | A medicinal antifungal and steroids cream comprising chitosan and a process to make it |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AU CA JP KR US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FR GB GR IT LU MC NL SE |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) |
Free format text: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1992911000 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2103351 Country of ref document: CA |
|
WWP | Wipo information: published in national office |
Ref document number: 1992911000 Country of ref document: EP |
|
WWR | Wipo information: refused in national office |
Ref document number: 1992911000 Country of ref document: EP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1992911000 Country of ref document: EP |